AstraZeneca has added another piece to its sprawling interface with CSPC Pharmaceutical, paying the Chinese biotech $30 million upfront to jointly discover and develop two kidney disease drug ...

United Therapeutics has paid $140 million to buy Thymmune Therapeutics for preclinical regenerative cell therapies focused on the thymus.

The Fosun subsidiary is paying the upfront fee, committing up to 1.12 billion yuan ($166 million) in milestones and agreeing ...

Roche’s investigational KRAS G12C inhibitor has beaten Amgen’s Lumakras and Bristol Myers Squibb’s Krazati in a phase 3 trial ...

Insilico Medicine has signed a deal worth up to $600 million with Takeda to collaborate on asset discovery across the Japan Big Pharma's therapeutic areas of interest.  | Insilico Medicine has signed ...

Merck & Co. has nixed the phase 2 study of a potential Alzheimer’s disease medicine after the drug underwhelmed in an interim analysis, marking another blow for the pharma’s struggling partner ...

Pacira BioSciences offloaded its cold-therapy pain relief device to medtech orthopedics specialist Zimmer Biomet in a deal ...

Ipsen is on a roll this week, scooping up its second biotech in three days in order to firm up its pipeline with promising clinical-stage candidates. This morning’s deal sees the French biopharma ...

QuantumCell has yet to discuss its plans for the program and has kept a low profile to date. (Alexander Sikov/iStock/Getty Images Plus) QuantumCell has licensed AlzeCure Pharma’s Alzheimer’s disease ...

In its recent fundraise and the 2024 $120 million series C that preceded it, Angitia chose to emphasize its work on AGA2118 and AGA2115 rather than AGA111. (iStock / Getty Images Plus) Coming on the ...

After serving at CBER for more than five years, Kumar was promoted to acting head of OTP by former CBER Director Vinay Prasad, M.D. (Stock Photo ) Vijay Kumar, the acting head of the FDA office that ...

U.S.-based Boulevard Bio is paying $20 million upfront (PDF) to China’s Metis TechBio for the global rights to a trispecific T-cell engager (TCE) for autoimmune diseases. The preclinical asset, dubbed ...